Results 121 to 130 of about 3,357,233 (168)

Abstract 7112: Preclinical profile of novel and potent small molecule inhibitors of PARG

Cancer Research
Abstract Poly(ADP-ribose) glycohydrolase (PARG) is primary enzyme involved in the dePARylation process of DNA repair, specifically in the single strand break repair (SSBRs). PARG is a macrodomain protein with exo- and endo-glycohydrolase activity that liberates free ADP-ribose and PAR chains, respectively.
Sukanya Patra, Manoj Pothuganti, Githavani Kummari, Venu Sankeshi, Jyothipriya Kapaka, Navnath Karche, Ramamohan Mekala, Srikant Viswanadha   +7 more
openaire   +1 more source

Abstract 6910: Synergistic tumor cell killing with dual inhibition of PARG and USP1

Cancer Research
Poly (ADP-ribose) glycohydrolase (PARG) is an enzyme that aid in DNA repair primarily through the removal of poly (ADP-ribose) (PAR) chains from PARylated proteins.
Ramya Ravindranathan, A. A. D. Da Costa, Benjamin P Lamarre, S. Mukkavalli, O. Somuncu, K. Parmar, G. Shapiro, Alan D. D’Andrea   +7 more
semanticscholar   +1 more source

Abstract A010: Synergistic ovarian cancer killing by combination of PARG and USP1 inhibitors: Role of single stranded DNA gaps as a predictive biomarker

Molecular Cancer Therapeutics
Poly(ADP-ribose) glycohydrolase (PARG), the primary de-PARylating enzyme, plays a critical role in resolving DNA damage. PARG inhibitors (PARGi) are currently in clinical development for patients with tumors exhibiting homologous recombination ...
Ramya Ravindranathan, Nicholas W. Ashton, A. A. D. Da Costa, O. Somuncu, Benjamin P Lamarre, S. Mukkavalli, K. Parmar, G. Shapiro, Alan D. D’Andrea   +8 more
semanticscholar   +1 more source

Abstract 1748: FORX-428: Exploiting PARG inhibition to target replication stress in cancer cells

Cancer Research
PARylation/dePARylation is essential for sensing and repairing replication-associated DNA damage. Inhibitors of the PARP enzymes catalyzing the build-up of poly(ADP-ribose) chains have become a mainstay of breast and ovarian cancer therapy over the ...
F. Zenke, Ulrich Lücking, Olivier Querolle, L. Iacovino, Marta Malattia, Alessandro Potenza, Nicolas Bocquet, Serena Bologna, Hanna Kok, Anika Kuster, Roxanne Lourman, Jason Clochard, Irena Konstantinova, T. Halazonetis, Jens U. Wuerthner, Tarig Bashir   +15 more
semanticscholar   +1 more source

INHIBITORS OF PARG

2023
CHANG PAUL, WIDDOWSON KATHERINE, AMES LISA J   +2 more
openaire   +5 more sources

PAR dysregulation in Huntington's disease: huntingtin immunofluorescence in PARG inhibitor-treated cells

, 2021
Tamara Maiuri, R. Truant
semanticscholar   +1 more source

PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy

Journal of Hepatology, 2022
Jia Fan, Bo Hu, Jian Zhou
exaly  

“PARG Inhibitors’ Success: A Long Way to Go!”

Current Enzyme Inhibition, 2015
Anuradha Pandey, Pooja Makhija, Prakash G.Chandak, Anil Bhanudas Gaikwad   +3 more
openaire   +1 more source

The Role of PTEN Loss in Modulating Cutaneous Melanoma Sensitivity to PARG Inhibitors

Poly (ADP-ribosylation) also known as PARylation, is a protein post-translation modification that is dynamically regulated by the opposing functions of PARP 1/2 and PARG. PARylation of proteins is critical for cellular functions such as maintenance of genomic stability, transcriptional activation, and apoptosis.
openaire   +1 more source

PARG INHIBITORS AND METHOD OF USE THEREOF

2022
YU XIAOCHUN, CHEN SHIH-HSUN, YUAN YATE-CHING, LI HONGZHI, HORNE DAVID   +4 more
openaire   +2 more sources